Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedemain Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
June 14, 2025 10:48 ET Â | Source: Celldex Therapeutics, Inc. 77% of…
Eternal’s Initiatives to Support Delivery Partners during the Heatwave
NEW DELHI, June 12, 2025 /PRNewswire/ -- In light of the ongoing…
